Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistent Cancers

Treatment Resistent Cancers

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression.

The Journal of clinical investigation·2026

Same author

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer.

Breast cancer research and treatment·2026

Same author

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.

Breast cancer research and treatment·2026

Same author

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence.

medRxiv : the preprint server for health sciences·2026

Same author

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

Search research articles

Related Experiment Video

Updated: Apr 18, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer.

Alexis LeVee¹, Maeve A Hennessy², Dame Idossa³

¹Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting

|April 16, 2026

Summary

Treatment for stage II-III triple-negative breast cancer (TNBC) is improving, but high recurrence rates necessitate new strategies. Research is exploring novel therapies and biomarkers to personalize care and improve outcomes for high-risk patients.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Apr 18, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Oncology
Immunotherapy
Breast Cancer Research

Background:

Stage II to III triple-negative breast cancer (TNBC) management is evolving with pembrolizumab integration.
Despite advances, a significant proportion of early-stage TNBC patients experience recurrence within 5 years.
There is a critical need for strategies to identify and treat high-risk TNBC patients.

Purpose of the Study:

To review recent advancements in stage II to III TNBC treatment.
To highlight emerging investigational therapies and combinations for TNBC.
To explore novel biomarker strategies for personalized TNBC care.

Main Methods:

Review of current literature on TNBC treatment and clinical trials.
Analysis of emerging therapeutic strategies like antibody-drug conjugates and immune checkpoint inhibitors.
Exploration of biomarker research including tumor-infiltrating lymphocytes and circulating tumor DNA.

Main Results:

Pembrolizumab combined with neoadjuvant chemotherapy has improved outcomes in early-stage TNBC.
Novel therapies including ADCs, anti-VEGF, dual immune blockade, and locoregional treatments are under investigation.
Biomarker strategies are being developed to identify high-risk patients and predict treatment response.

Conclusions:

Advances in immunotherapy and targeted therapies are transforming TNBC treatment.
Biomarker discovery is crucial for personalizing treatment and improving outcomes in high-risk TNBC.
Continued research into novel agents and combinations is essential for addressing TNBC recurrence.